Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The gene expression profiles of leukemia cells isolated from spleens of CreMx-1 CPSF6-RARG mice and Wt1F/+CreMx-1 CPSF6-RARG mice

ABSTRACT: The gene expression profiles of leukemia cells isolated from spleens of CreMx-1 CPSF6-RARG mice and Wt1F/+CreMx-1 CPSF6-RARG mice

PROVIDER: PRJNA1018457 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26103458_1.fastq.gz	Fastqsanger.gz
	SRR26103458_2.fastq.gz	Fastqsanger.gz
	SRR26103459_1.fastq.gz	Fastqsanger.gz
	SRR26103459_2.fastq.gz	Fastqsanger.gz
	SRR26103460_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

The gene expression profiles of leukemia cells isolated from spleens of CreMx-1;CPSF6-RARG mice and Wt1F/+CreMx-1;CPSF6-RARG mice

Project description:We found that CPSF6-RARG fusion gene drives the aberrant expansion of HSCs and progenitor cells, which may lead to a preleukemic phenotype. Moreover, wt1 haploinsufficiency cooperates with RARG fusions to induce AML. To investigate the mechanism by which Wt1 haploinsufficiency cooperates with RARG fusion overexpression to induce AML in vivo, we analyzed the gene expression profiles of leukemia cells isolated from CreMx-1;CPSF6-RARG mice and Wt1F/+CreMx-1;CPSF6-RARG mice through RNA-seq.

2024-10-15 | GSE243415 | GEO

Analysis of the chromatin accessibility in CPSF6-RARG or NUP98-RARG overexpressing hCD34+ cells compared to control hCD34+ cells using ATAC-seq.

Project description:We found that RARG fusions selectively upregulated BCL2 and ATF3 in HSPCs, driving uncontrolled proliferation and disrupting the differentiation of RARG-AML cells.To investigate the mechanism how RARG fusions mediate activation of their downstream targets such as BCL2 and ATF3, we defined the chromatin accessibility using ATAC-seq assay in human CD34+ (hCD34+) cells with or without CPSF6::RARG or NUP98::RARG overexpression.

2024-10-16 | GSE275304 | GEO

Identifying RARG fusions or PML-RARA binding genes or analysis the epigenetic changes (H3K27ac, H3K4me1, and H3K4me3) in hCD34+ cells overexpressing CPSF6::RARG and NUP98::RARG.

Project description:To understand how RARG fusion proteins regulate their target genes in the hematopoietic system, we overexpressed fusions or PML-RARA in hCD34+ cells and identified target genes that are regulated by RARG fusions. We found that RARG fusions selectively upregulated BCL2 and ATF3 in HSPCs, driving uncontrolled proliferation and disrupting the differentiation of RARG-AML cells.To investigate the mechanism how RARG fusions mediate activation of their downstream targets such as BCL2 and ATF3, we dected the epigenetic changes (H3K27ac, H3K4me1, and H3K4me3) associated with RARG fusions binding in hCD34+ cells overexpressing CPSF6::RARG and NUP98::RARG.

2024-10-16 | GSE275303 | GEO

The effect RARG fusion genes or PML-RARA overexpression in human CD34+ cells on the gene expression.

Project description:Currently, AML with RARG rearrangements (RARG AML), including NUP98-RARG, PML-RARG, CPSF6-RARG, NPM1-RARG, and HNRNPC-RARG, has been identified as a novel entity of AML. Overexpression of RARG fusions in human CD34+ cells promoted the expansion of immature myeloid cells, reduced the percentage of mature granulocytes, inhibited the differentiation of myeloid cells, and self-renewal abilities of hCD34+ cells. To understand how RARG fusion proteins regulate their target genes in the hematopoietic system, we first expressed HA-tagged X-RARG fusions or HA-tagged PML-RARA in hCD34+ cells. We then analyzed the differential genes expression in hCD34+ cells with or without RARG fusion genes or PML-RARA overexpression through RNA-seq.

2024-10-15 | GSE243437 | GEO

Acute myeloid leukemia with CPSF6-RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration.

Project description:Some subtypes of acute myeloid leukemia (AML) share morphologic, immunophenotypic, and clinical features of acute promyelocytic leukemia (APL), but lack a PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) fusion gene. Instead, they have the retinoic acid receptor beta (RARB) or retinoic acid receptor gamma (RARG) rearranged. Almost all of these AML subtypes exhibit resistance to all-trans retinoic acid (ATRA); undoubtedly, the prognosis is poor. Here, we present an AML patient resembling APL with a novel cleavage and polyadenylation specific factor 6 (CPSF6)-RARG fusion, showing resistance to ATRA and poor response to chemotherapy with homoharringtonine and cytarabine. Simultaneously, the patient also had extramedullary infiltration.

| S-EPMC7797573 | biostudies-literature

Identifying RARG fusions or PML-RARA binding genes or analysis the epigenetic changes (H3K27ac, H3K4me1, and H3K4me3) in hCD34+ cells overexpressing CPSF6::RARG and NUP98::RARG.

Project description:Identifying RARG fusions or PML-RARA binding genes or analysis the epigenetic changes (H3K27ac, H3K4me1, and H3K4me3) in hCD34+ cells overexpressing CPSF6::RARG and NUP98::RARG.

| PRJNA1150541 | ENA

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [RNA-seq]

Project description:Acute myeloid leukemia (AML) with RARG fusions, which clinic features resemble acute promyelocytic leukemia (APL), have been identified as a new subtype with poor clinical outcomes. The underlying mechanism of RARG fusion is poorly understood, which needs to be explored urgently to develop effective therapeutic strategies. Using hematopoietic specific knock-in mouse model and xenograft mouse model transplanted with oncogene transduced human CD34+ cells, we revealed that CPSF6-RARG (CR) fusion, one of the most prevalent recurrent RARG translocations, enhances expansion of immature cells and impairs myeloid maturation, synergizing with RAS mutation to drive more aggressive myeloid malignancies. Mechanistically, CR recruits the histone deacetylase 3 (HDAC3) to suppress the transcription of PU.1, a key transcription factor for myeloid lineage specification. CR driven leukemia is more sensitive to HDAC inhibitors in vitro and in vivo. Hence, our data reveals the molecular bases of the oncogenic CR fusion and provides a potential targeted therapeutic approach against AML with CR fusions.

2024-10-24 | GSE243817 | GEO

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [CR-N_mice_scRNA-seq]

2024-10-24 | GSE247606 | GEO

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [CUT&Tag in CD34+ cells]

2024-10-24 | GSE245012 | GEO

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [human CD34+ cells_CUT-Tag seq_HDAC3]

2024-10-24 | GSE273551 | GEO